MENA Newswire, BEIJING: Researchers in China have reported evidence that non-invasive sound therapy can induce measurable biological changes linked to Alzheimer’s disease, marking a potential advance in non-drug approaches to the condition, according to findings published in a peer-reviewed scientific journal. The study focused on the effects of low-frequency auditory stimulation on aged non-human primates and adds to a growing body of research examining how sensory-based interventions may influence brain function associated with neurodegenerative disorders.
The research was conducted by scientists at the Kunming Institute of Zoology under the Chinese Academy of Sciences and involved the use of a 40-hertz sound frequency, which lies within the normal range of human hearing. This frequency has been studied previously in laboratory mice, where rhythmic sensory stimulation was shown to influence the accumulation of proteins associated with Alzheimer’s pathology. The latest study extends this line of investigation to rhesus monkeys, whose brain structure and aging processes more closely resemble those of humans.
In the experiment, nine elderly rhesus monkeys were exposed to the 40-hertz auditory stimulation for one hour each day over a seven-day period. Researchers monitored changes in the animals’ cerebrospinal fluid, which plays a role in clearing waste products from the brain. Measurements taken shortly after the treatment period showed a marked increase in the levels of Alzheimer’s-related proteins in the cerebrospinal fluid, a change interpreted by the researchers as an indication of enhanced clearance activity from brain tissue.
Follow-up assessments conducted five weeks after the conclusion of the sound exposure indicated that the observed changes persisted beyond the treatment window. According to the researchers, the sustained effect suggests that short-term auditory stimulation can trigger longer-lasting physiological responses related to brain waste removal. The study did not involve behavioral testing or cognitive assessments, focusing instead on biochemical markers associated with Alzheimer’s disease.
Alzheimer’s disease is a progressive neurodegenerative condition characterized by the accumulation of beta-amyloid plaques and tau protein tangles in the brain. These changes are associated with declining memory, impaired reasoning, and reduced ability to perform daily activities. Existing treatments approved in several countries primarily aim to slow disease progression and are often based on antibody therapies that target amyloid proteins. While such treatments have shown measurable effects in some patients, they can be costly and may carry risks, including brain swelling or bleeding.
Use of 40 hertz auditory stimulation in neuroscience
The sound-based approach examined in the study differs from pharmacological treatments by seeking to influence neural activity patterns rather than introducing drugs into the body. The 40-hertz frequency used in the experiment is associated with gamma oscillations, a type of brain rhythm linked to cognitive processes such as attention and memory. Previous research has indicated that gamma oscillations may play a role in coordinating brain activity and supporting the movement of cerebrospinal fluid through neural tissue.
Scientists involved in the study reported that the auditory stimulation appeared to enhance the function of the brain’s waste-clearance pathways, which are thought to become less efficient with age. Impairment in these pathways has been linked to the accumulation of proteins associated with Alzheimer’s disease. By stimulating specific neural rhythms, the researchers aimed to promote the natural mechanisms involved in maintaining brain health.
The findings align with broader international research efforts exploring non-invasive brain stimulation techniques. Studies conducted in other countries have examined combinations of light and sound stimulation, as well as ultrasound-based methods, to influence brain activity and protein clearance. Some early-stage human studies have reported changes in brain markers following sensory stimulation, though large-scale clinical trials are still limited.
Limitations of non-human primate studies
The researchers emphasized that the current study was conducted in non-human primates and does not establish clinical effectiveness in humans. They noted that further research, including controlled human trials, would be required to assess safety, optimal treatment parameters, and potential therapeutic value for people with Alzheimer’s disease. The study was designed to investigate biological mechanisms rather than clinical outcomes.
As populations age worldwide, Alzheimer’s disease continues to place increasing pressure on healthcare systems and families. According to international health agencies, the number of people living with dementia is expected to rise significantly in coming decades. Research into non-invasive and drug-free approaches remains an active area of scientific inquiry, with the goal of expanding the range of options available for managing neurodegenerative conditions based on established biological evidence.